Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK. Kizhakeyil A, et al. Among authors: goh yt. Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0. Mol Cancer. 2021. PMID: 34654425 Free PMC article. No abstract available.
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH. Tan D, et al. Among authors: goh yt. Leuk Res. 2013 Sep;37(9):1070-6. doi: 10.1016/j.leukres.2013.06.008. Epub 2013 Jun 28. Leuk Res. 2013. PMID: 23816344
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, Ng SC, Fadilah S, Kim WS, Goh YT; SGH651 Investigators. Tan D, et al. Among authors: goh yt. Lancet Haematol. 2015 Aug;2(8):e326-33. doi: 10.1016/S2352-3026(15)00097-6. Epub 2015 Jul 7. Lancet Haematol. 2015. PMID: 26688485 Clinical Trial.
Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, Phipps C, Lee YS, Grigoropoulos NF, Lao Z, Surendran S, Teh EM, Goh YT, Chng WJ, Gopalakrishnan SK. Chen Y, et al. Among authors: goh yt. Blood Cancer J. 2016 Jul 29;6(7):e450. doi: 10.1038/bcj.2016.62. Blood Cancer J. 2016. PMID: 27471866 Free PMC article. No abstract available.
The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, Tang T, Goh AZ, Ghosh A, Ng HJ, Gopalakrishnan S, Loh Y, Lim ST, Hwang W, Tan D, Goh YT. Phipps C, et al. Among authors: goh yt, goh az. Leuk Lymphoma. 2018 Oct;59(10):2336-2341. doi: 10.1080/10428194.2017.1422863. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345210
Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma.
Chan JY, Ng AYJ, Cheng CL, Nairismägi ML, Venkatesh B, Cheah DMZ, Li ST, Chan SH, Ngeow J, Laurensia Y, Lim JQ, Pang JWL, Nagarajan S, Song T, Chia B, Tan J, Huang D, Goh YT, Poon E, Somasundaram N, Tao M, Quek RHH, Farid M, Khor CC, Bei JX, Tan SY, Lim ST, Ong CK, Tang T. Chan JY, et al. Among authors: goh yt. Blood Cancer J. 2018 Nov 12;8(11):111. doi: 10.1038/s41408-018-0149-5. Blood Cancer J. 2018. PMID: 30420729 Free PMC article. No abstract available.
Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia.
Ong SY, Phipps C, Nagarajan C, Tang T, Lim ST, Goh YT, Lee YS. Ong SY, et al. Among authors: goh yt. Leuk Lymphoma. 2020 Jan;61(1):225-227. doi: 10.1080/10428194.2019.1648805. Epub 2019 Aug 5. Leuk Lymphoma. 2020. PMID: 31379229 No abstract available.
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, Grigoropoulos NF, Nairismägi ML, Ng CCY, Rajasegaran V, Hong H, Kim SJ, Cho J, Tse E, Mow B, Cai QC, Poon LM, Cai QQ, Tan J, Chan JY, Lim JX, Goh YT, Phipps C, Rötzschke O, Cheng CL, Ha JCH, Khoo LP, Loh YSM, Au-Yeung R, Chan TS, Kwong YL, Hwang W, Kim WS, Bei JX, Lin T, Ong CK, Lim ST. Lim JQ, et al. Among authors: goh yt. Leukemia. 2020 Dec;34(12):3413-3419. doi: 10.1038/s41375-020-1000-0. Epub 2020 Aug 5. Leukemia. 2020. PMID: 32753688 Free PMC article. No abstract available.
164 results